Protein arginine methyltransferase 5 (PRMT5) has been implicated in the development and progression of human cancers. However, few studies reveal its role in epithelial-mesenchymal transition (EMT) of pancreatic cancer cells. In this study, we find that PRMT5 is up-regulated in pancreatic cancer, and promotes proliferation, migration and invasion in pancreatic cancer cells, and promotes tumorigenesis. Silencing PRMT5 induces epithelial marker E-cadherin expression and down-regulates expression of mesenchymal markers including Vimentin, collagen I and β-catenin in PaTu8988 and SW1990 cells, whereas ectopic PRMT5 re-expression partially reverses these changes, indicating that PRMT5 promotes EMT in pancreatic cancer.
| INTRODUC TI ON
Pancreatic cancer is the most common malignancy of the pancreas, with a dismal 5-year survival rate of less than 5% and a median survival of <11 months. This dismal outcome can be attributed to the lack of early diagnoses and effective interventions. Additionally, conventional treatment approaches such as surgery, chemotherapy and radiation have generally had little impact on the course of this aggressive cancer despite efforts over the past several years. 1 Therefore, the detection and diagnosis of pancreatic cancer in the early stage are extremely urgent.
Emerging evidence has demonstrated that epithelial-mesenchymal transition (EMT) plays an essential role in the progression of pancreatic cancer. 2 It is a biologic process in which epithelial cells transform into special cells with mesenchymal phenotypes, resulting in enhanced invasion and metastasis. Concomitantly, epithelial markers such as E-cadherin are down-regulated, whereas mesenchymal markers including Vimentin, collagen I and β-catenin are up-regulated. 3 In 2019, a study provided evidence for the positive effects of SLC34A2 on EMT phenotype in glioma cell lines via the EGFR/PI3K/AKT signalling. 4 However, the molecular mechanisms that act upstream of these factors in various physiological and pathologic contexts in pancreatic cancer are not well characterized. Therefore, it is necessary to discover the specific mechanism in pancreatic cancer to provide novel prognostic and treatment targets.
Protein arginine methyltransferases (PRMTs) plays critical roles in a variety of cellular processes including transcriptional regulation, chromatin regulation, signal transduction, RNA processing and DNA damage repair. 5 PRMT5, the type II protein arginine transferase, catalyses the symmetrical dimethylation of arginine residues on histone and non-histone substrates and plays multiple roles in cellular processes, including differentiation, proliferation, apoptosis and ribosome biogenesis. 6 Furthermore, several studies have shown that PRMT5 plays an important role in the development and progression of human cancers including glioblastoma, 7 colorectal cancer, 8 breast cancer, 9 lymphoma, 10 prostate cancer 11 and lung cancer. 12 Recently, Menin and PRMT5 were found to suppress Glucagon-like-peptide-1 receptor (GLP1R) transcription to inhibit the proliferation of β-cell in pancreatic diseases. 13 In addition, PRMT5 was proved to inhibit the tumour suppressor FBW7, resulting in increasing c-Myc levels to promote the proliferation of and aerobic glycolysis in pancreatic cancer cells. 14 In this study, we examined the roles of PRMT5 in pancreatic cancer and elucidated the underlying mechanism. Our data showed that PRMT5 promoted cell proliferation, migration and invasion in pancreatic cancer cells, and promoted tumorigenesis. Importantly, PRMT5 promoted EMT probably via EGFR/AKT/βcatenin pathway.
| MATERIAL S AND ME THODS

| Cell lines and culture conditions
The pancreatic cancer cell lines PaTu8988 and SW1990 were obtained from ATCC (USA) and Cancer Cell Repository (Shanghai, China). Cells were maintained in Dulbecco's Modified Eagle's Medium (DMEM) with 10% foetal bovine serum (FBS) at standard cell culture conditions (37°C, 5% CO 2 in humidified incubator). DMEM, FBS and trypsin were purchased from Gibco (Invitrogen).
| Plasmids construction
The oligo sequence of sh-PRMT5-3′UTR included: PRMT5 shRNA 
| Lentivirus production and cell infection
The packaging plasmid psPA ×2 and the envelope plasmid pMD2.G were purchased from Sigma (MO, USA). PLKO.1-sh-PRMT5 vector was cotransfected with psPA ×2 and pMD2.G into HEK293T cells using Lipofectamine2000 (Invitrogen). Viruses were harvested 48 hours after transfection, and viral titres were determined. Cells were infected with 1 × 10 6 recombinant lentivirus transduction units in the presence of 8 mg/mL polybrene (Sigma).
Puromycin (1:10 000 dilutions) was added to cells until the cells in blank group died off.
| Transient transfection
The plasmids pHA-venus and pHA-PRMT5 were kind gifts from Professor Mo. Cells were plated in six-well plates at a density of 4 × 10 5 cells/well. After 24 hours of culture, the medium was replaced by Opti-MEM (Invitrogen) and cultured. In total, 2 μg plasmid was transfected using 6 μL Lipofectamine ® 2000 Transfection Reagent. After incubation for another 48 hours, the treated cells were determined using Western blot analysis, transwell or cell counting Kit-8 assay.
| Western blot
Whole-cell lysates were prepared and Western blot was carried out as recently described. 15 The following antibodies were used: PRMT5, β-tubulin, collagen I (Abcam), E-cadherin, Vimentin, β-catenin, p-EGFR (Y1068), EGFR, (Cell Signaling Technology), Akt, p-Akt, GSK-3β, p-GSK-3β, p-EGFR (Y1172), HA (ImmunoWay) and
HRP-conjugated secondary antibodies (Pierce).
| Cell counting kit-8 assay
The measurement of viable cell mass was performed with Cell
Counting Kit-8 (Promega) according to manufacturer's instructions.
Briefly, 3000 cells/well were seeded in a 96-well plate, grown in an incubator (5% CO 2 , 37°C). Respectively in first day, second day, third day and fourth day, 10 μL CCK-8 was added to each well, cells were incubated at 37°C for 2 hours, and the absorbance was finally determined at 490 nm.
| Colony formation assay
Cells were seeded in six-well plates at a density of 1000 cells per well and cultured in incubator (5% CO 2 , 37°C) for two weeks.
At the end of the incubation, the cells were fixed with 4% paraformaldehyde, stained with 0.1% crystal violet. Megascopic cell colonies were counted using Image-Pro Plus 5.0 software (Media Cybernetics). Colony formation rate = (number of colonies/number of seeded cells) × 100%. Each measurement was performed in triplicate, and the experiments were each conducted at least three times. Each test was repeated in triplicate.
| Cell migration assay
| Cell invasion assay
Cell invasion was determined using a Boyden chamber assay. 5 × 10 4
PaTu8988 cells and 1 × 10 5 SW1990 cells were seeded in serum-free DMEM in the upper wells, which have already been covered with a layer of BD Matrigel Basement Membrane. The cells were later processed similar to that of cell migration assay, photographed (×20) in five independent fields for each well, and counted. Each test was repeated in triplicate. 
| Xenograft mouse model
| qRT-PCR
Total RNA was extracted using RNAiso Plus (Takara). Reverse 
TA B L E 1 DNA and RNA nucleotide sequences
The primers for qRT-PCR were in Table 1 . Samples were cycled once at 95°C for 2 minutes and then subjected to 35 cycles of 95°C, 56°C
and 72°C for 30 seconds each. The relative mRNA content was calculated using the 2 −ΔΔCt method with GAPDH as an endogenous control.
| EGFR inhibitor
Cells were incubated in culture medium with 10% FBS supplemented with EGFR inhibitor (Erlotinib, CP-358774, MCE) over the concentration range 0, 10 μmol/L. 16 Cells were harvested at 72 hours after treatment.
| Statistical analysis
All statistical analyses were carried out using the SPSS statistics software package. All data are presented as mean ± SD from at least three independent experiments. Comparisons between groups were analysed using the Student's t test (two groups) or an one-way ANOVA (multiple groups). Kaplan-Meier survival was 
| RE SULTS
| PRMT5 is profiled in pancreatic cancers and different pancreatic cancer cells
To confirm the clinical relevance of PRMT5 expression, we first analysed the PRMT5 protein expression in clinical specimens from the human protein atlas (www.prote inatl as.org). We found that PRMT5
had the positive strong expression in pancreatic cancer and negative weak expression in normal pancreas ( Figure 1A ). Furthermore, we analysed the PRMT5 mRNA level in clinical specimens from oncomine (www.oncom ine.org). We found that PRMT5 mRNA level was higher in pancreatic cancer tissues than that in normal pancreatic tissues (1.03 ± 0.48 vs 1.60 ± 0.39, P < .001, n = 78) in Badea pancreas database ( Figure 1B) . These results suggest that PRMT5
is up-regulated in pancreatic cancer. Figure 1E ). Moreover, further analysis showed that PRMT5 expression in stage I was lower than that in stage II + III + IV groups ( Figure 1F ).
| PRMT5 promotes cell proliferation in pancreatic cancer cells and tumorigenesis
To investigate the effects of PRMT5 on cell growth in pancreatic cancer cells, we first used the CCK8 assay to determine the growth curves and then evaluated their ability of colony formation. As showed in Figure 2A 
| PRMT5 promotes cell invasion in pancreatic cancer cells
Then, we examined the effect of PRMT5 on the invasive abilities Figure 3J ). It is suggested that PRMT5 plays a major role on the cell invasion in pancreatic cancer cells.
| PRMT5 promotes EMT via activating EGFR/ AKT/β-catenin signalling in pancreatic cancer cells
To probe the molecular basis for PRMT5-enhanced cell motility, we Figure 4A-F) . The above results indicated that PRMT5 promoted pancreatic cancer proliferation, invasion, migration and EMT. To investigate the possible mechanism, we tested the effect of PRMT5 knockdown on invasion-related signalling ( Figure 5A-B ). We found that PRMT5 knockdown decreased the phosphorylation level of AKT, as well as its downstream p-GSK-3β, and then resulted in β-catenin down-regulation. Expectedly, ectopic PRMT5 re-expression reversed these changes. Previous study proved that EGFR is methylated by an arginine methyltransferase PRMT5. 17 Considering EGFR as the upstream signalling of AKT pathway, we speculate that EGFR signalling also regulates PRMT5-induced EMT in pancreatic cancer cells. So, we utilized the Western blot to detect the level of EGFR, p-EGFR (Y1068) and p-EGFR (Y1172). As observed in Figure 5A 
| D ISCUSS I ON
In this study, we confirm that PRMT5 is overexpressed in human pancreatic cancer at both mRNA and protein levels, and acts as an independent prognostic factor for patient outcome. Furthermore, we find that PRMT5 promotes EMT via stimulating EGFR/AKT/βcatenin pathway for the first time. All these findings suggest that PRMT5 may function as an oncogene and be a candidate for diagnosis and prognosis in pancreatic cancer.
Previous studies have determined that PRMT5 may function as an oncogene to promote cancer cell growth. 18, 19 For example, Li Z et al 20 found that PRMT5 promoted cell proliferation, tumorigenicity, tumour invasion and metastasis as LINC01138 acted as an oncogenic driver. Deng X et al 11 found that PRMT5 promotes prostate cancer cell growth by epigenetically activating transcription of the androgen receptor (AR) in prostate cancer cells. Especially in lung cancer cells, PRMT5 was proved to promote cell proliferation through direct interaction with Akt and regulation of Akt activity. 21 More recently, PRMT5 was demonstrated that lead to FBW7 expression to promote tumorigenesis in pancreatic cancer. 14 ling, 24 and EGF-induced nuclear translocation of SHCBP1 directly increased acetylation of β-catenin to enhanced NSCLC cellular stemness, 25 which is suggested that EGFR signalling can drive β-catenin activation via various routes. In this study, we provide a novel F I G U R E 2 PRMT5 promotes cell proliferation in pancreatic cancer cells and tumorigenesis. A-B, CCK-8 assay showed that PRMT5 knockdown inhibited PaTu8988 and SW1990 cell growth rate (Student's t test:*P < .05). C-D, Clone formation assays in PaTu8988 and SW1990 cells. PRMT5 knockdown inhibited cell clone formation (Student's t test:*P < .05). The number of clones with at least 50 cells per colony and strong, high dense staining was counted. The rates of colony formation were 48.33% and 17.67% in sh-EGFP and sh-PRMT5 PaTu8988 cells, and 35.67% and 10.67% in sh-EGFP and sh-PRMT5 SW1990 cells, respectively. E-F, PaTu8988 cells with PRMT5 downregulation were injected (2.0 × 10 6 cells/site) subcutaneously into a mice, and the tumour volume was measured weekly (n = 5 mice). *P < .05. G-H, CCK-8 assay showed that ectopic PRMT5 re-expression in PaTu8988 and SW1990 sh-PRMT5 stable infected cells promoted cell proliferation rate (Student's t test: *P < .05). I-J, Clone formation assays in PaTu8988 and SW1990 sh-PRMT5 stable infected cells. Ectopic PRMT5 re-expression in PaTu8988 and SW1990 sh-PRMT5 stable infected cells promoted cell clone formation (Student's t test: ***P < .001).
The rates of number of colonies (defined as ≥50 cells) were 25.33% and 56.67% in PaTu8988 cells, 18.67% and 58.33% in SW1990 cells, respectively. K-L, SW1990 cells with PRMT5 up-regulation were injected (2.0 × 10 6 cells/site) subcutaneously into a mice, and the tumour volume was measured weekly (n = 5 mice), *P < .05 1148. 17 Herein, we for the first time find that PRMT5 promotes the autophosphorylation of EGFR at Y1068 and Y1172 to activate Aktβ-catenin axis in pancreatic cancer cells.
In summary, our study provides proof that PRMT5 promotes EMT in pancreatic cancer cells probably through activating EGFR/AKT/βcatenin signalling. And a noteworthy feature of our study is that we find the expression of p-EGFR (Y1068) and p-EGFR (Y1172) is increased remarkably. Above all, we for the first time established the link F I G U R E 3 PRMT5 promotes cell migration and invasion in pancreatic cancer cells. A-B, The migration changes were measured by transwell assay in PaTu8988 and SW1990 sh-PRMT5 stable infected cells (Student's t test: **P < .01, ***P < .001 PaTu8988 and SW1990 cells transfected with pHA-PRMT5 plasmid. *P < .05, **P < .01, ***P < .001 between PRMT5 and EGFR/AKT/β-catenin signalling in pancreatic cancer. All these findings suggest that PRMT5 is a potential biomarker for diagnostics and prognosis of pancreas cancer.
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